General Proximity is a biotechnology company that develops next-generation induced-proximity medicines using its proprietary OmniTAC platform to target previously undruggable proteins
General Proximity is a biotechnology company that develops next-generation induced-proximity medicines using its proprietary OmniTAC platform to target previously undruggable proteins. The company focuses on creating bifunctional therapeutics for oncology, cardiometabolic disease, and neurodegeneration.